Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Prospective controlled trial on endurance exercise training in adult sickle cell disease patients
source: American Society of Hematology
year: 2017
authors: Barnabas Gellen, Laurent Messonnier, Angele Merlet, Etienne Audureau, Thomas Rupp, Sandrine Peyrot, Cyril Martin, Jean-Antoine Ribeil, jean Benoit Arlet, Frédéric Galactéros, Leonard Feasson, Pablo Bartolucci
summary/abstract:Sickle cell disease (SCD) is the most common inherited disease worldwide. Because favoring the risk of vaso-occlusive crises (VOC), SCD patients are banned from strenuous exercise. We hypothesized that a well-controlled moderate-intensity endurance exercise training (EET) program could improve SCD patients without provoking VOC.
Patients and Methods: We conducted a prospective, multicenter, controlled study with individually tailored Blood lactate-guided (BL) endurance training on a cycloergometer for 8 weeks in adult SCD patients. The primary end point was the submaximal incremental cardio-pulmonary exercise testing (CPET) at a BL concentration of 4 mmol.L-1. Secondary endpoints were: CPET at a BL 2.5 mmol/L and at the first lactic threshold (LT1), BL levels at given workload level (Female: 40W and Male: 60W), safety (pain, VOC and acute chest syndrome), biological and echocardiography parameters, pulmonary function test (PFT), 6-minute walk test (6MWT), quality of life (QoL) and muscle properties and vascularization (biopsy of vastus lateralis muscle).
Results: Forty homozygous SCD patients (33±10 years, 23 male) were included. Four patients (3 EET and 1 control) were lost to follow-up. Data of 33 patients (15 EET and 18 controls) were analyzed. EET and control patients were comparable at baseline with regard to CPET, clinical, biological, and resting cardiorespiratory parameters. EET patients presented a significant increase of CPET workload at BL4 (p=0.031), BL2.5 (p=0.003) and LT1 (p<0.0001) compared to the control group that remained unchanged. BL levels at a given level decreased significantly by 18% in the EET group compared to control group (p=0.01). Among the 40 randomized patients, 5 MAE occurred in the control group and 2 in the EET group. Quality of life improved for vitality (p=0.04) and physical activity (p=0.03) in the EET group compared to control group. Thigh biopsy showed in the EET group a significant increase of the proportion of oxidative type I fibers and of COX activity, paralleled by a significant increase in capillary density. No significant alterations were found in the control group. No change was found according to biological and echocardiography parameters, 6MWT and pulmonary function test.
organization: APHP CHU Henri Mondor Albert Chenevier, CRETEIL, France; Université Savoie Mont Blanc, Chambery, France; Université Lyon 1, Villeurbanne Cedex, FRA; APHP Necker, Paris, France; APHP Hôpital Européen Georges Pompidou, paris, France; Laboratoire Interuniversitaire de Biologie de la Motricité, St Etienne, France; Unité de Myologie, CHU St Etienne, St Etienne, France; IMRB UPEC, Créteil, Franceread more
+myBinderRelated Content
-
Patient-reported experience measure in sickle cell diseaseObjectives: To develop patient-reported...
-
Playing through sickle cellEighteen minutes in with no break, Billy...
-
The neglected and forgotten Sickle Cell Disease – A silent mass killer in Kenyahttps://www.youtube.com/watch?time_conti...
-
Tionne ‘T-Boz’ Watkins to dish on her Incurable disease, TLC Stardom and left eye’s death in new m...Many storms have come and gone...
-
Endocrine and Metabolic Complications in Children and Adolescents With Sickle Cell Disease: An Italian Cohort StudyBackground: Children with Sickle Cell D...
-
Sickle Cell Mommies ClubThis is a place for moms with children w...
-
Increasing Appointment Attendance: A Vital Opportunity to Improve Health Outcomes for Those Living with Sickle Cell ...Sickle cell disease (SCD) affects approx...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.